Skip to Main Content

Paper Details

A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma.
Clin Genitourin Cancer
8
2021
Author NameAffiliation
Dexiang GaoUniversity of Colorado Cancer Center, University of Colorado Anschutz Medical Campus
  • 1 - 1

Datasets

Release 1.2